Nasdaq · Healthcare
Lifevantage Corp (LFVN)
As-reported financials and recent SEC filings for Lifevantage Corp, latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$228.5M
Net income
$9.8M
Net margin
4.3%
Diluted EPS
$0.75
ROE
28.3%
P/E (TTM)
—
Market cap
—
Debt / equity
—
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $228.5M | $200.2M | $213.4M | $206.4M | $220.2M |
| Gross profit | $183.7M | $158.7M | $170.0M | $168.3M | $182.0M |
| Operating income | $12.2M | $4.3M | $4.3M | $7.6M | $17.6M |
| Net income | $9.8M | $2.9M | $2.5M | $3.1M | $12.9M |
| Diluted EPS | $0.75 | $0.23 | $0.20 | $0.24 | $0.90 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
SCHEDULE 13G/A2026-07-06
View on EDGAR →42026-07-06
View on EDGAR →42026-07-06
View on EDGAR →42026-07-06
View on EDGAR →42026-06-17
View on EDGAR →42026-06-05
View on EDGAR →1442026-06-03
View on EDGAR →8-K2026-05-06
View on EDGAR →Largest Healthcare peers
Go deeper on LFVN
Search Lifevantage Corp’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeOr check your whole portfolio free — no account needed.
Data sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.